Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESTRO 2026 | Same-day single-fraction SABR for lung cancer maintains treatment quality and improves patient ease

Neil Wallace, MD, Peter MacCallum Cancer Centre, Melbourne, Australia, describes the benefits of same-day single-fraction stereotactic ablative body radiotherapy (SABR) in lung cancer patients, emphasizing the patient-centered nature of the treatment. Staff surveys about the treatment process found that the quality of the treatment was maintained as the convenience was improved. Dr Wallace highlights the cohorts that would benefit are patients who need to travel for treatment and frail patients, for whom traveling to hospital is difficult. This interview took place at the European Society for Radiotherapy and Oncology 2026 Congress in Stockholm, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.